Classen Immunotherapies, Inc. v. Biogen Idec
Classen Immunotherapies, Inc. v. Biogen Idec
Opinion
United States Court of Appeals for the Federal Circuit ______________________
September 12, 2011 ERRATA ______________________
2006-1634, -1649
CLASSEN IMMUNOTHERAPIES, INC., Plaintiff-Appellant,
v.
BIOGEN IDEC, Defendant-Appellee,
and
GLAXOSMITHKLINE, Defendant-Appellee,
and
MERCK & CO., INC., Defendant-Cross Appellant,
and
CHIRON CORPORATION, KAISER-PERMANENTE, INC., KAISER PERMANENTE VENTURES, KAISER PERMANENTE INTERNATIONAL, KAISER PERMANENTE INSURANCE COMPANY, THE PERMANENTE FEDERATION, LLC, THE PERMANENTE COMPANY, LLC, THE PERMANENTE FOUNDATION, THE PERMANENTE MEDICAL GROUP, INC., KAISER FOUNDATION HOSPITALS, KAISER FOUNDATION ADDED CHOICE HEALTH PLAN, INC., and KAISER FOUNDATION HEALTH PLAN INC.,
Defendants. ______________________
Decided August 31, 2011 Precedential Opinion ______________________
Please make the following change:
Page 2, the following corrections
Donald R. Ware, Foley Hoag LLP, of Boston, Massachu- setts, for defendant-appellee, Biogen IDEC. With him on the brief were Barbara A. Fiacco and Jeremy A. Younkin. Of counsel were Joshua M. Hiller, Wilmer Cutler Pickering Hale and Dorr LLP, of Boston, Massachusetts, and David A. Wilson, of Washington, DC.
Reference
- Status
- Unpublished